This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Oxygen Biotherapeutics Signs Agreement To Sell DERMACYTE Products To Mexican Sales And Distribution Company

MORRISVILLE, N.C., March 10, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has entered into an agreement with independently owned and operated Comercial Uni2, S.A. de C.V. of Mexico, for the sale of DERMACYTE products. Per the terms of the agreement, Comercial Uni2 has exclusive rights to sell and distribute Oxygen Biotherapeutics' DERMACYTE ® skin care products throughout Mexico.

Oxygen Biotherapeutics, Inc. logo

Per the agreement, Comercial Uni2 commits to purchase a total of 10,000 units of DERMACYTE products over the next year. An escalating purchase requirement is in effect for the following four years. The agreement also includes an option for Comercial Uni2 to add Central America as a territory.

"Oxygen-based skin care treatments are at the cutting edge of today's cosmetics.  DERMACYTE skin care lotions provide a unique value proposition in a growing Mexican cosmetics market," said Felix Bautista, owner of Comercial Uni2 S.A. de C.V.  Co-owner, Luc Albert, agreed:  "DERMACYTE skin care lotions form a perfect fit under our firm's mission to distribute differentiating products in Mexico."

According to DataMonitor Research, the market for skincare in Mexico increased at a compound annual growth rate of 5.2% between 2004 and 2009. The facial care category led the skincare market in Mexico, accounting for a share of 51.3%. The National Chamber of the Perfumery, Cosmetics and Toiletries Industry of Mexico anticipates 5% growth in the cosmetics and toiletries sector for 2010, the latest number available.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs